Literature DB >> 15724244

Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles.

Katrin Schwarz1, Edwin Meijerink, Daniel E Speiser, Alain C Tissot, Indulis Cielens, Regina Renhof, Andris Dishlers, Paul Pumpens, Martin F Bachmann.   

Abstract

Induction of high frequencies of specific T cells by vaccination requires prime-boost regimens. To reach optimal immune responses, it is necessary to use different vectors for priming and boosting as e.g. DNA vaccination followed by boosting with a recombinant viral vector. Here, we show that vaccines based on virus-like particles (VLP) displaying peptide epitopes are equally effective to induce CTL responses if used in a homologous or heterologous prime-boost setting. Strikingly, high frequencies (>20% of CD8(+) cells) of protective CTL could be induced and maintained by weekly injection of VLP. Thus, the use of VLP may avoid the requirement for complicated heterologous prime-boost regimens, facilitating the development of effective T cell-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15724244     DOI: 10.1002/eji.200425755

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

1.  Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer.

Authors:  T Lin; S Liang; F Meng; Q Han; C Guo; L Sun; Y Chen; Z Liu; Z Yu; H Xie; J Ding; D Fan
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza.

Authors:  Dustin P Patterson; Agnieszka Rynda-Apple; Ann L Harmsen; Allen G Harmsen; Trevor Douglas
Journal:  ACS Nano       Date:  2013-04-10       Impact factor: 15.881

3.  A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.

Authors:  Lukai Zhai; Julianne Peabody; Yuk-Ying Susana Pang; John Schiller; Bryce Chackerian; Ebenezer Tumban
Journal:  Antiviral Res       Date:  2017-09-20       Impact factor: 5.970

4.  Development of a new hydrogen peroxide–based vaccine platform.

Authors:  Ian J Amanna; Hans-Peter Raué; Mark K Slifka
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

5.  Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation.

Authors:  Patrick Lacasse; Jérôme Denis; Réjean Lapointe; Denis Leclerc; Alain Lamarre
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

6.  Effects of Signal 3 during CD8 T cell priming: Bystander production of IL-12 enhances effector T cell expansion but promotes terminal differentiation.

Authors:  Weiguo Cui; Nikhil S Joshi; Aimin Jiang; Susan M Kaech
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

Review 7.  Engineering virus-like particles as vaccine platforms.

Authors:  Kathryn M Frietze; David S Peabody; Bryce Chackerian
Journal:  Curr Opin Virol       Date:  2016-03-29       Impact factor: 7.090

Review 8.  Protein-based nanoparticles in cancer vaccine development.

Authors:  Medea Neek; Tae Il Kim; Szu-Wen Wang
Journal:  Nanomedicine       Date:  2018-10-04       Impact factor: 5.307

Review 9.  Harnessing Nanoparticles for Immunomodulation and Vaccines.

Authors:  Ariane C Gomes; Mona Mohsen; Martin F Bachmann
Journal:  Vaccines (Basel)       Date:  2017-02-14

10.  Advanced antigen delivery of murine survivin: chimeric virus-like particles in cancer vaccine research.

Authors:  Thomas Schumacher; Claus Ruehland; Christine Schultheiss; Marc Brinkman; Franz Roedel; Christian O A Reiser; Juergen Hess; Christoph Reichel
Journal:  Int J Biomed Sci       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.